Phaseline

Targets › PIK3CB

PIK3CB (Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform): drug programs, companies and trials

9 programs from 8 companies in 25 trials: 16 Phase 2, 7 Phase 1, 2 Phase 3; Oncology, Infectious disease, Neurology; next expected readout Dec 2026.

Phosphoinositide-3-kinase (PI3K) phosphorylates phosphatidylinositol derivatives at position 3 of the inositol ring to produce 3-phosphoinositides. Uses ATP and PtdIns(4,5)P2 (phosphatidylinositol 4,5-bisphosphate) to generate phosphatidylinositol 3,4,5-trisphosphate (PIP3). (UniProt, P42338)

Open in Phaseline: the race on PIK3CB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
CelcuityGedatolisib
Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor
MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CAPhase 3Breast Cancer; mCRPC (Metastatic Castration-resistant Prostate Cancer); Endometrial Cancer; TNBC - Triple-Negative Breast CancerDec 2026
ThromBioTBO-309
PI3Kβ inhibitor that blocks platelet activation, adhesion, and aggregation
PIK3CBPhase 2Ischemic Stroke; Acute Ischemic StrokeDec 2026
The First Affiliated Hospital of Xiamen UniversityDuvalisib
Dual phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase kinase 4 (MEK)
PIK3CA, PIK3CB, MAP2K4Phase 2Peripheral T Cell LymphomaDec 2026
National Cancer Institute (NCI)GSK2636771
PI3K-beta inhibitor
PIK3CBPhase 2Advanced LymphomaDec 2026
Institute of Hematology & Blood Diseases Hospital, ChinaLinperlisib
PI3K inhibitor
PIK3CA, PIK3CB, PIK3DPhase 2Relapsed/Refractory Large B-Cell Lymphoma; Lymphoma, T-CellDec 2026
National Cancer Institute (NCI)Taselisib (GDC-0032)
PI3-kinase class I inhibitor
PIK3R1, PIK3CB, PIK3CG, PIK3CA, PIK3R2Phase 2Advanced LymphomaMar 2027
RestorbioDactolisib (BEZ235)
Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor
MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CAPhase 2Respiratory Tract Infections; Covid19–
Eli LillySamotolisib (LY3023414)
Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor
MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CAPhase 1Breast Neoplasms; Endometrial CancerDec 2026
SovargenPaxalisib (SVG103)
PI3-kinase class I inhibitor
PIK3R1, PIK3CB, PIK3CG, PIK3CA, PIK3R2Phase 1Focal Cortical Dysplasia; Primary Central Nervous System Lymphoma; Glioblastoma; CDK Gene Mutation …Feb 2027

Conditions

Advanced Lymphoma (3) Breast Cancer (2) Endometrial Cancer (2) Relapsed/Refractory Large B-Cell Lymphoma (1) Lymphoma, T-Cell (1) Respiratory Tract Infections (1) Covid19 (1) Ischemic Stroke (1) Acute Ischemic Stroke (1) Peripheral T Cell Lymphoma (1) mCRPC (Metastatic Castration-resistant Prostate Cancer) (1) TNBC - Triple-Negative Breast Cancer (1)

Modalities

small molecule (8), mixed (1)

Companies

National Cancer Institute (NCI) (2) Institute of Hematology & Blood Diseases Hospital, China (1) Restorbio (1) ThromBio (1) The First Affiliated Hospital of Xiamen University (1) Celcuity (1) Eli Lilly (1) Sovargen (1)

Related targets

PIK3CA (7) PIK3R1 (5) PIK3CG (5) MTOR (3) PIK3R2 (2) PIK3D (1) MAP2K4 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.